Background Specialised surveillance using total body photography and digital dermoscopy to monitor people at very high risk of developing a second or subsequent melanoma has been reported as cost effective. Objectives We aimed to estimate the 5-year healthcare budget impact of providing specialised surveillance for people at very high risk of subsequent melanoma from the perspective of the Australian healthcare system.
Introduction
Cutaneous melanoma is potentially lethal, but detection at an early stage is associated with better survival [1] . Individuals are typically considered at very high risk of primary melanoma if they carry a genetic mutation that predisposes them to melanoma, or if they have a personal history of melanoma and either a strong family history of melanoma or over 100 moles with multiple atypical nevi, or if they have a history of multiple primary melanomas [2] . Clinical practice guidelines recommend that individuals at very high risk of melanoma be identified early so that surveillance interventions can be targeted efficiently [2] . In Australia, melanoma is the third most common cancer in adults [3] , and patients are currently cared for in a variety of general and specialised clinical settings, with surveillance methods and intervals dependent on the patient's doctor. A study conducted at a metropolitan hospital in Sydney found that specialised surveillance consisting of 6-monthly patient review, monitoring using total body photographs and sequential digital dermoscopy imaging was an efficient way to manage individuals at very high risk of melanoma, resulting in a benign-malignant excision ratio of 1.6:1 [4] . Our economic evaluation conducted from the Australian health system perspective found that specialised surveillance conducted in a hospital clinic was cost effective compared with routine care [5] . The main drivers of the cost effectiveness were earlier stage of melanoma diagnosis and fewer excisions in specialised surveillance compared with routine care, resulting in lower morbidity and treatment costs. These results were robust when tested in sensitivity analyses. For specialised surveillance to be implemented in the Australian healthcare system as usual practice for the management of individuals at very high risk of melanoma, a budget impact analysis is required to forecast the change in how health system resources will be used and to calculate the impact on national healthcare spending.
Methods

Analytical Framework
We developed a budget analysis impact model using Microsoft Ò Excel 2010 to estimate the costs of a specialised surveillance programme, assuming all very highrisk patients in the Australian population were eligible following diagnosis of a melanoma. Costs for this analysis were calculated annually and over 5 years, based on the number of patients with a newly diagnosed melanoma entering the surveillance programme and the number of years accrued under surveillance. It was assumed that patients who accessed specialised surveillance remained in the programme over subsequent years. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) principles of good practice framework was used to guide the framework for this analysis [6] .
Perspective and Time Horizon
Costs were measured from the perspective of the Australian healthcare system, with a base year of 2017 and a 5-year time horizon to reflect health system budget planning cycles.
Scenarios
Time of diagnosis provides an opportune moment to identify very high-risk individuals, and we examined two scenarios for provision of specialised surveillance within this analysis: (1) 100% of eligible patients can access specialised surveillance, and (2) a shortage of service providers means that 60% of eligible patients access specialised surveillance in year 1, rising to 90% in years 4 and 5 ( Fig. 1 
in the Electronic Supplementary Material [ESM]).
Costs
The costs of surveillance of very high-risk patients for both specialised surveillance and routine care were obtained from the first 5 years of a published decision analytic model [5] . All excision costs were included regardless of whether the lesions were found to be benign or malignant. Future costs were not discounted. Confidence intervals around the excision rates were calculated from 1000 patient-level simulations by time for each strategy using TreeAge Pro 2017, R1.1 (TreeAge Software). Each patient was assumed to be independent, and variables were randomly sampled from a specified distribution to calculate a cost per patient by year of surveillance in both specialised surveillance and routine care.
All costs for specialised surveillance and routine care were analysed as health system costs and included the cost of one full-body skin examination (two per year for specialised surveillance and one per year for routine care), diagnosis (histopathology), and treatment for melanoma and non-melanoma skin cancers, including lesion excision and subsequent management based on stage at diagnosis. For routine care, costs were included for both general practitioner (64%) and specialist dermatologist (36%) consultations according to usual care practices in the community [7] . Specialised surveillance costs were included for public hospital clinic time and staffing costs, an additional full-body skin examination, total body photographs and dermoscopy digital monitoring [5] . Individual costs and the decision analytic model have been previously described [5] and are reproduced in Tables 1-3 and Figs. 2-3 in the ESM. Costs were inflated to year 2017 Australian dollar ($AU) values [8] and converted to $US using the Organisation for Economic Co-operation and Development (OECD) purchasing power parities index [9] . Patient out-of-pocket costs were not included.
Estimation of the Eligible Very High-Risk Population
Published epidemiological data were used to estimate the percentage of the population at very high risk of melanoma based on the risk factors dysplastic nevus syndrome [10] [11] [12] , family history [13] [14] [15] [16] , multiple primary melanomas [10, 17, 18] , and CDKN2A mutation carriers [19] [20] [21] and to estimate the proportion of very high-risk patients who had more than one risk factor [4] . The budget impact analysis was based on the expected annual diagnosis of any melanoma (in situ or invasive) in individuals at very high risk of melanoma in the Australian population, as the risk of subsequent melanoma is similar for those diagnosed with in situ and those diagnosed with invasive melanoma [22, 23] . We estimated the national annual incidence of invasive [24] and in situ [25] melanoma based on published Australian data. The mortality rate for individuals diagnosed with a melanoma in the same year was calculated using 2012 incidence and prevalence data [26, 27] . Five-year relative survival data based on being alive after 1 year were used to calculate expected mortality [28] . The size of the population was held constant over the 5-year period based on projections for melanoma incidence to remain stable between the years 2017 and 2021 [24] .
Sensitivity Analysis
We tested the impact on costs due to (1) a change in incidence of melanoma incidence projections by ± 5%, (2) an increase in the proportion of in situ melanomas relative to all melanomas and (3) different proportions of risk factors based on estimates in the literature [10, 12-14, 19, 20, 29, 30] .
Results
Base Case
We estimated that, based on 21,373 (13,465 invasive, 7908 in situ) melanomas diagnosed annually, 3778 (17.7%) patients would be identified as at very high risk of melanoma based on the high-risk features of family history, multiple primary melanomas, dysplastic naevus syndrome and CDKN2A mutation status (Table 1) .
In the first year, the mean cost of specialised surveillance was $AU 1574 [95% confidence interval (CI) 1101-2047] and of routine care was $AU 1754 (95% CI 1154-2354). The annual mean costs increased with years under surveillance, as the cost of surveillance included excision costs of benign and malignant lesions and the ongoing treatment costs of any melanomas diagnosed. Excision and ongoing melanoma treatment costs were higher in routine care than in specialised surveillance because, on average, there were more excisions and detection of later-stage melanomas ( Table 4 in the ESM). If all eligible patients diagnosed with melanoma received specialised surveillance, the cost for the first year of monitoring would be $AU 5.9 million (95% CI 4.1-7.6) compared with $AU 6.5 million (95% CI 4.3-8.8) for routine care; at year 5, costs would be $AU 32.0 million (95% CI 24.5-39.5) for monitoring compared with $AU 43.4 million (95% CI 30.4-56.5) for routine care. The cumulative cost over this period would be $AU 93.5 million (95% CI 82.0-105.0) for specialised surveillance compared with $AU 120.7 million (95% CI 102.0-139.4) for routine care. If the initial uptake of specialised surveillance was assumed to be 60% of the very high-risk population in year 1, rising to 90% in years 4 and 5, the cost of specialised surveillance in year 1 would be $AU 6.1 million (95% CI 4.2-8.1) and at year 5 would be $AU 33.8 million (95% CI 25.6-42.0), with a cumulative cost over 5 years of $AU 98.1 million (95% CI 90.4-105.8). The total cost savings to the Australian healthcare system over 5 years would be $AU 27.2 million (95% CI 20.0-34.4) if all eligible patients accessed specialised surveillance and $AU 22.6 million (95% CI 11.6-33.6) if access to specialised surveillance was incremental ( Fig. 1 ; Tables 4  and 5 in the ESM).
Sensitivity Analysis
Compared with baseline costs, if all eligible patients diagnosed with melanoma received specialised surveillance, an increase in melanoma incidence of 5% increased the total 5-year cost of specialised surveillance by $AU 4.5 million and that of routine care by $AU 5.8 million; specialised surveillance with a realistic staggered uptake increased costs by $AU 5.0 million ( Table 6 in the ESM). Total health system savings over 5 years would increase with both total and staggered uptake in the eligible population by $AU 1.3 million and $AU 1.2 million, respectively. Increasing in situ melanoma to equal the number of invasive melanoma would increase the very high-risk patient population by 27%, representing an additional 1000 patient presentations annually. Compared with baseline, if all eligible patients diagnosed with melanoma received specialised surveillance, the total 5-year cost would increase by $AU 25.0 million for specialised surveillance, by $AU 32.3 million for routine care, and by $AU 26.1 million with a staggered uptake. Health system savings over this period would increase by $AU 7.3 million if all eligible patients received specialised surveillance and by $AU 6.2 million if the introduction of the service was staggered ( Table 6 in the ESM). Estimates in the literature for the proportion of individuals at very high risk among individuals diagnosed with melanoma were relatively consistent, and one-way sensitivity analyses had a minor impact on costs (data not shown).
Discussion
As far as we are aware, this analysis is the first to estimate the potential health system costs and savings associated with implementing a national, specialised surveillance programme for individuals at very high risk of melanoma. Based on Queensland Cancer Registry data [25] for first reports of invasive and in situ melanomas, where in situ reports comprised 37% of total first melanoma reports c Family history: It has been estimated that 10% of melanomas occur in the context of a positive family history [15] . Aitken et al. [13] calculated that high-risk families comprised 4.7% of familial melanoma d Dysplastic nevus syndrome: Newton et al. [11] using population data, reported that 15% of individuals who had a melanoma also had AMS. AMS phenotype was defined as having at least three of five possible high-risk features: two or more clinically atypical nevi, more than 100 nevi[2 mm or[50 nevi if aged[50 years, nevi abnormally distributed, nevi in anterior scalp or iris pigmented lesions e Based on population estimates by Aitken et al. [19] f Estimates for the proportion of people who have a subsequent melanoma (9%) based on Ferrone et al. [10] g Estimate of total number of high-risk individuals allowing for individuals meeting more than one criteria, based on data from the High-Risk Clinic, Royal Prince Alfred Hospital, Sydney, Australia [4] 
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Routine/current surveillance provision Specialised surveillancefull uptake Specialised surveillancestaggered uptake Years Fig. 1 Health system costs for the first 5 years following introduction of a specialised surveillance programme for patients at very high risk of melanoma. The cost of routine current care (blue line) is compared with full access to specialised surveillance services (red line) and staggered access (green line) to specialised surveillance, with services increasing from 60 to 90% in years 4 and 5. Staggered access includes the cost of individuals receiving routine surveillance provision in the community Specialised surveillance, compared with existing routine care in the community, has the potential to lead to cost savings of between $AU 20 million and $AU 34.4 million for the Australian healthcare system over a 5-year period. For both strategies, surveillance included the cost of detecting and treating melanoma and non-melanoma skin cancers. Our previous cost-effectiveness study [5] found that excision rates and stage of melanoma at diagnosis were the most important cost drivers. In deterministic sensitivity analysis, the probability of excision in routine care was the only variable to impact the incremental cost-effectiveness ratio of $AU 50,000 per quality-adjusted life-year (QALY) [5] .
Currently in Australia, specialised surveillance has not been implemented nationally and there is no subsidy for skin surveillance monitoring in the Medicare Benefits Schedule (MBS). Patients face significant direct out-ofpocket costs and opportunity costs because specialised surveillance requires longer appointment times (especially for patients with many moles) [4] and a requirement to return for early review (3 months) if a suspicious lesion is monitored rather than excised [31] . As has been observed for breast cancer screening programmes [32] , uptake and adherence to specialised melanoma surveillance may be lower in regional and remote regions of Australia than in urban areas because people are less likely to travel long distances to access specialist melanoma and treatment services [7] and because accessing dermatologists can be difficult with their relatively low numbers [33] and clustering in metropolitan areas [34] . The provision of specialised surveillance by trained general practitioners in addition to specialist dermatologists would therefore be important for ensuring access and adherence to the proposed national specialised surveillance programme.
A limitation of this study is that we had to estimate the number of individuals diagnosed with a first in situ and subsequent melanoma as these figures are not routinely reported by cancer registries. The estimates of incidence of in situ melanomas from Queensland data may be low as they spanned 25 years, and the number of incident in situ melanomas has been increasing [29, 35] . Australian in situ melanoma rates [3] were recently reported to almost equal those for invasive melanomas [27] , so we examined this issue in the sensitivity analysis and found that it increased the very high-risk patient population by 27%. The proportion of patients with a subsequent melanoma has been reported at 3-10% [10, 22, [36] [37] [38] , but not all studies have used data containing both primary and subsequent in situ and invasive melanomas. Our estimate of 9% is conservative as it is based only on subsequent invasive melanoma following an invasive or in situ melanoma. A change in 3% of the proportion of the population with a subsequent melanoma would lead to an annual increase in the potential high-risk population of 470 individuals (a 12% increase).
A widespread concern about specialised surveillance is that it may lead to an increase in skin biopsy rates (i.e. overtreatment) [35] . However, our cost-effectiveness study [5] found surveillance did not lead to more excisions than routine care; in fact, the specialised surveillance group underwent fewer excisions. While it is possible that performance bias led to a reduction in the number of excisions [39] (the study was conducted in a hospital dermatology clinic, and participants were not blinded), the probability of an excision and the mean number of excisions per patient were relatively stable in both groups over the 5-year study period. Many factors are associated with the decision to excise a lesion, including level of training, patient requests, appointment duration and intervals between appointments [40] . A further concern about more intensive surveillance is over-diagnosis [41] , where malignant lesions that would not have caused any harm if left untreated may be excised. We were unable to assess over-diagnosis using our data.
While the evidence regarding harms of skin cancer screening in the general population are limited [42] , psychological distress is commonly experienced by patients with melanoma [43] , and regular follow-up for very highrisk patients may also provide reassurance [44] . Over the study period [4] , only 3% of patients withdrew from participation in the specialised surveillance programme; however, patient costs were subsidised by grant funding during the study period, which minimised out-of-pocket costs. We based our identification of eligible high-risk patients to coincide with a melanoma diagnosis, when individuals were already interacting with the healthcare system. We therefore did not include costs associated with finding the target population or determining eligibility. A further consideration is that some potential costs, such as training and administering accreditation programmes or data management systems for auditing, were not included as a cost of specialised surveillance as these could be incurred by professional organisations or individual clinicians. Although educational programmes are available to enable general practitioners to improve their melanoma diagnostic skills, this training may need to be formalised, perhaps through a professional organisation such as the Royal Australian College of General Practitioners (RACGP), to ensure that general practitioners are skilled in dermoscopy and providing specialised skin surveillance. In addition, the cost for provision of information to patients following diagnosis regarding self-skin examination or psychological support could be considered.
We used the broad perspective of the Australian healthcare system in this analysis, recognising that our healthcare system is funded through federal and state mechanisms, includes treatment in public and private hospitals and includes both general and specialist doctors. Most cost estimates were based on MBS item numbers, which are nationwide, and assumed that total body photography and sequential digital dermoscopy were funded through the MBS. Australia has a large geographic variation in the distribution of incident melanomas and population demographics, therefore the proportion of patients with melanoma meeting these high-risk criteria may differ across Australia; thus, the budget impact on hospital costs will also likely differ by state. Further research could examine budget impact at a state level.
It is important to note that one of the drivers of savings under specialised surveillance was that melanomas were detected at an earlier stage and there were fewer excisions compared with care in the community. We assumed that specialised surveillance of high-risk patients would continue to be performed by clinicians proficient in dermoscopy and short-and long-term monitoring. The costs for specialised surveillance assumed a hospital setting and could decrease slightly if provided elsewhere. The mean annual cost of a melanoma diagnosis is estimated to be between $AU 1681 and 115,109 per patient depending on stage at diagnosis [45] . Health system savings with specialised surveillance are likely to increase over time, as later diagnosis incurs ongoing hospital and treatment costs, and a greater proportion of patients not undergoing specialised surveillance presented with later-stage disease [5] . New treatments and therapies for stages III and IV melanoma are very costly and would further increase health service costs above those estimated here [46] . Further research is needed to examine the viability of extending the programme to a broader population of patients with melanoma who would be considered at increased risk and who could be identified using a risk-prediction tool [47] . We observed high rates of participation and adherence to the specialised surveillance programme, high satisfaction with care, and reassurance from regular follow-up. The specialised surveillance programme should be monitored to observe whether excision rates, melanoma stage at diagnosis, participation and long-term adherence are maintained. Collecting data on excision rates would provide confidence for decision makers about the viability of an extended programme. Other payment models for clinicians, such as activity-based funding, could also be considered as this might discourage unnecessary excisions and other treatments, whilst better acknowledging the time required for full-body skin examination, digital monitoring and patient education [48] .
Conclusions
While people at very high risk of melanoma are a relatively small subset of all patients with melanoma, the provision of specialised surveillance has the potential to be both more efficient and more effective from the health system perspective than the prevalent unstructured service use. Successful implementation of specialised surveillance would be dependent on patients' adherence to long-term regular review. Scheduling a Medicare rebate should improve patient outcomes by facilitating the extra service provision to patients and supporting access to a specialist or general practitioner with the appropriate melanoma diagnostic skills.
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